Jared Kaltwasser | Authors


MCL35 Assay Stratifies Risk in Patients With Mantle Cell Lymphoma

December 21, 2020

A new multi-analyte prognostic assay has demonstrated the potential to risk-stratifying patients with mantle cell lymphoma based on the particular molecular signature of an individual patient’s cancer, according to a new study.

Surveillance for Second Primary Malignancy Recommended in Select Patients With Myelofibrosis Treated With Ruxolitinib

December 15, 2020

Patients with myelofibrosis who receive ruxolitinib appear to face a higher risk of second primary malignancy; these risks are suggested to be even higher in men and patients with a history of arterial thrombosis and prolonged hydroxycarbamide exposure.

New Community-Setting Data Affirm Ibrutinib’s Efficacy in R/R MCL

November 25, 2020

New data show patients with mantle cell lymphoma who were treated with ibrutinib in a community setting had similar outcomes to patients given the Bruton’s tyrosine kinase inhibitor in a clinical trial setting, a retrospective study showed.

Task Force Recommends Active Surveillance for Many Low-Risk Papillary Thyroid Microcarcinoma Patients

November 19, 2020

Active surveillance can be a safe and appropriate management strategy for patients with T1aN0M0 low-risk papillary thyroid microcarcinoma, though the decision to use the strategy requires multidisciplinary teams and patient input, according to a new report.